Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Despite being mostly low-grade, cytokine release syndrome, skin-related events, and dysgeusia were frequent side effects of talquetamab therapy. Patients who had multiple myeloma that was relapsed or resistant after receiving substantial prior treatment had a significant response to talquetamab.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form